help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bajoria, R.
Right arrow Articles by Fisk, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bajoria, R.
Right arrow Articles by Fisk, N. M.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 10 3399-3407
Copyright © 1997 by The Endocrine Society


Original Studies

Transport and Metabolism of Thyrotrophin-Releasing Hormone Across the Fetal Membrane1

Rekha Bajoria, Timothy A. Ryder and Nicholas M. Fisk

Royal Postgraduate Medical School, Institute of Obstetrics and Gynaecology, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG United Kingdom

Address all correspondence and requests for reprints to: Rekha Bajoria, Royal Postgraduate Medical School, Institute of Obstetrics and Gynaecology, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG United Kingdom. E-mail: rbajoria{at}rpms.ac.uk

To determine the transfer and metabolism of TRH by human fetal membranes, the bidirectional transport and uptake of TRH was investigated by adding 125I-labeled TRH (100,000 cpm) or commercial TRH either to the maternal or the fetal compartment of an in vitro model of cultured human fetal membranes obtained from term and preterm placenta. Transmembrane transfer was also studied in the presence of 200 µM p-hydroxy-mercuriphenyl-sulphonic acid (p-HMSA), a dipeptidase enzyme inhibitor. Creatinine and heparin were used as an internal markers. Metabolites of TRH were separated from intact molecules by gel filtration on Sephadex G-10. The structural integrity of the membrane was confirmed by electron microscopy.

The transmembrane transfer of radiolabeled and commercial TRH were comparable across both preterm and term placenta. When transport was studied from the maternal to fetal side, the maternal concentration of TRH declined rapidly from 100% at time 0 to 19.31 ± 2.26% at 8 h with a concomitant increase in the fetal concentration from undetectable to a maximum of 2.56 ± 0.38% with a fetomaternal ratio of 0.16 ± 0.01. Transfer of TRH from the fetal to maternal compartment was similar to that of maternal to fetal. Chromatography of maternal and fetal media showed that TRH was metabolized by the membrane into small molecular weight fragments. Treatment of the membrane with p-HMSA increased TRH transport from the maternal to fetal compartment to 18.12 ± 0.91 (P < 0.001) with an fetomaternal ratio of 0.35 ± 0.02 (P < 0.001). Although transmembrane transfer of TRH from the fetal to maternal side was also increased by p-HMSA, levels achieved were less than that from maternal to fetal (12.26 ± 1.50%; P < 0.05). These results suggest that the human fetal membrane acts as an enzymatic barrier to the bidirectional transfer of TRH from 24 weeks gestation.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society